Medicare Wegovy Prescriptions Surge After Heart Disease Coverage Expansion

Medicare has seen a sharp increase in prescriptions for the weight loss drug Wegovy since the program expanded coverage to include people with heart disease. The move allows certain Medicare beneficiaries with a history of cardiovascular problems to access the medication for both weight management and heart health. This policy change represents a significant shift in how Medicare approaches obesity treatments with proven cardiovascular benefits.

• Medicare prescription claims for Wegovy rose dramatically after coverage was expanded for people with heart disease.
• The policy change allows Medicare Part D plans to cover Wegovy for beneficiaries with a history of heart attack, stroke, or other cardiovascular conditions.
• The expansion follows clinical trial data showing semaglutide, the active ingredient in Wegovy, can reduce the risk of major adverse cardiovascular events.
• Experts expect continued growth in Wegovy prescriptions as awareness of the expanded coverage spreads among doctors and patients.

Background on Wegovy and Medicare

Wegovy, a brand name for semaglutide, was originally approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Until recently, Medicare Part D plans generally did not cover drugs prescribed solely for weight loss due to a statutory exclusion. However, the program can cover such medications if they are approved for a different medical use.

In March 2024, the FDA expanded Wegovy’s label to include reducing the risk of major adverse cardiovascular events in adults with overweight or obesity who also have established cardiovascular disease. This approval opened the door for Medicare coverage under Part D for beneficiaries who meet those criteria. According to the original report by News-Medical, prescription claims for Wegovy spiked shortly after the coverage expansion took effect.

Details of the Coverage Expansion

Under the new policy, Medicare Part D plans may cover Wegovy for beneficiaries who have both a body mass index (BMI) of 27 or higher and a history of cardiovascular disease, such as a heart attack or stroke. The coverage is based on the drug’s FDA-approved indication for cardiovascular risk reduction, not solely for weight loss. This distinction allows Medicare to bypass the traditional exclusion for weight loss drugs.

The Centers for Medicare & Medicaid Services (CMS) has not made Wegovy a mandatory Part D drug, meaning coverage decisions are at the discretion of individual plan sponsors. Nonetheless, many plans have chosen to include the medication on their formularies, and the News-Medical analysis shows a steep rise in prescriptions since the expansion was announced.

Reasons Behind the Spike

Several factors have contributed to the surge in Medicare Wegovy prescriptions. First, the expanded label provides a clear medical justification for coverage that aligns with Medicare’s rules. Second, clinical evidence from the SELECT trial demonstrated that semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 20% in people with overweight or obesity and preexisting cardiovascular disease. This data convinced many physicians to prescribe Wegovy for heart health in addition to weight loss.

Additionally, patient demand has increased as news of the cardiovascular benefits reaches older adults who are at higher risk for heart disease. The News-Medical report highlights that the number of monthly prescription claims for Wegovy among Medicare beneficiaries jumped significantly in the months following the coverage announcement, with no signs of slowing down.

Implications for Patients and the Healthcare System

The coverage expansion may improve access to an effective treatment for millions of Medicare beneficiaries who struggle with obesity and heart disease. However, the high cost of Wegovy, which can exceed $1,300 per month before insurance, remains a barrier. While Medicare coverage reduces out-of-pocket costs for enrolled patients, the overall expense could put pressure on Part D budgets and potentially affect premiums.

Healthcare providers are beginning to incorporate Wegovy into cardiovascular risk management protocols. The News-Medical analysis suggests that the prescription trend is likely to continue as more clinicians become aware of the coverage change and the supporting evidence. Long-term, this shift may lead to broader Medicare coverage of other weight loss drugs that demonstrate similar cardiovascular benefits.

What the SELECT Trial Actually Showed

The policy did not change on a hunch. It changed because of SELECT, the large cardiovascular outcomes trial that tested semaglutide 2.4 mg, the Wegovy dose, in adults who were overweight or obese and already had established cardiovascular disease but did not have diabetes. Over several years of follow-up, participants taking semaglutide had roughly a 20 percent lower risk of major adverse cardiovascular events, a combined measure of heart attack, stroke, and death from cardiovascular causes, compared with those on placebo. The trial enrolled more than 17,000 people, large enough that regulators and Medicare took the signal seriously.

What makes SELECT different from the weight-loss trials is the endpoint. STEP measured pounds. SELECT measured heart attacks and strokes. That distinction is the entire legal basis for Medicare coverage, because Part D is allowed to pay for a drug treating a covered condition such as cardiovascular disease even when it is excluded for weight loss alone. The FDA label update in early 2024 turned the trial into an approved indication, and the coverage followed the label rather than the other way around.

One nuance worth holding onto: the cardiovascular benefit in SELECT was only partly explained by weight loss. Participants did shed weight, but the risk reduction appeared earlier and larger than weight change alone would predict, which points to additional effects on blood pressure, inflammation, and the blood vessels themselves.

Who Actually Qualifies Under the New Rule

Coverage is narrower than the headlines suggest. To have a realistic shot at Medicare paying for Wegovy under the cardiovascular indication, a beneficiary generally needs to meet all of the following:

• Established cardiovascular disease. This means a documented history such as a prior heart attack, prior stroke, or peripheral artery disease. Being at risk for heart disease is not the same as having it, and plans check for the actual diagnosis.
• Overweight or obesity. A body mass index of 27 or higher, which matches the FDA label for the cardiovascular indication.
• Enrollment in a Part D plan that lists Wegovy. Coverage is not mandatory, so whether your specific plan pays depends on that plan’s formulary for the year.
• A prescription written for cardiovascular risk reduction, not for weight loss, with the supporting diagnosis codes in the chart.

If any of those pieces is missing, the claim can be denied even when the drug itself sits on the formulary. The most common reason for denial is a missing or unclear cardiovascular diagnosis in the prescribing record, which is a paperwork problem, not a clinical one.

How Do I Check Whether My Plan Covers It?

Do not assume. Formularies change every plan year, and two people on the same street can have different Part D plans with different answers. A practical sequence:

1. Find your plan’s formulary, the list of covered drugs, on your insurer’s site or in your annual plan documents, and search for Wegovy. Note the tier and whether it carries a prior authorization or step-therapy requirement.
2. Call the member services number on your card and ask specifically whether Wegovy is covered for cardiovascular risk reduction, and what documentation the prior authorization requires.
3. Ask your prescriber’s office to submit the prior authorization with your cardiovascular history attached. This is where most approvals are won or lost.
4. If denied, ask about the plan’s exception and appeal process. Denials are frequently overturned when the cardiovascular diagnosis is documented clearly on appeal.

What Wegovy Costs, and Why Copay Cards Do Not Help on Medicare

The list price of Wegovy runs north of $1,300 per month before any insurance. When a Part D plan covers it, your share depends on the plan’s tier structure and where you sit in the coverage phases across the year. Here is the part that surprises people: the manufacturer copay savings cards that commercially insured patients use to knock the price down are, by federal anti-kickback rules, not usable by anyone on Medicare or other government insurance. That is why a neighbor with an employer plan might pay a small copay while a Medicare beneficiary pays far more for the identical pen.

Two things can genuinely lower the cost for Medicare beneficiaries. The first is the Extra Help program, the Part D Low-Income Subsidy, which sharply reduces drug costs for those who qualify by income. The second is the annual out-of-pocket cap on Part D spending, now in place, which limits how much any one beneficiary pays for covered drugs in a year. Neither makes Wegovy cheap, but both change the math for people who clear the coverage hurdle.

How Does Semaglutide Protect the Heart, Not Just the Waistline?

It helps to understand why a weight-loss injection ended up with a cardiovascular label. Semaglutide is a GLP-1 receptor agonist, and its effects reach well beyond appetite:

• Weight and visceral fat. Losing weight, especially the fat packed around the organs, lowers the workload on the heart and improves how the body handles blood sugar.
• Blood pressure. GLP-1 medications tend to nudge systolic blood pressure down modestly, and that compounds over years.
• Inflammation. Markers of inflammation such as high-sensitivity CRP typically fall, and vascular inflammation is part of what drives heart attacks and strokes.
• Blood sugar and insulin. Even in people without diabetes, steadier glucose and lower insulin reduce metabolic strain on the arteries.
• Direct vascular effects. Research suggests GLP-1 signaling acts on the blood vessel lining itself, which may explain why the benefit in SELECT outpaced what weight loss alone would predict.

The takeaway for a patient is that the drug is doing several things at once, which is also why the people who benefit most tend to be those whose cardiometabolic numbers were off to begin with. Knowing those numbers, blood pressure, ApoB, HbA1c, fasting insulin, and hs-CRP, is how you and your clinician judge whether the medication is actually moving your risk, not just the number on the scale.

Side Effects and Who Should Be Cautious

The cardiovascular news should not erase the safety conversation. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst during dose increases and easing over time. Slowed stomach emptying can aggravate reflux and, less commonly, contribute to gallbladder problems. Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodent studies, so it is not for people with a personal or family history of medullary thyroid carcinoma or MEN2. It is not appropriate during pregnancy, and anyone with a history of pancreatitis should weigh the risk with their clinician. For older Medicare beneficiaries in particular, the appetite drop can cut protein intake enough to speed up muscle loss, so protein and resistance activity matter more, not less, once the medication is working.

Where Zepbound and Other GLP-1 Drugs Fit

Wegovy is not the only GLP-1 medication, but it is the one with the cardiovascular label that unlocked this specific Medicare pathway. Zepbound (tirzepatide) produces greater average weight loss in its trials and gained an indication for obstructive sleep apnea in adults with obesity, which can open a different coverage door, but it does not carry the same cardiovascular-risk-reduction indication that drove the Wegovy coverage change. Ozempic, the diabetes-labeled version of semaglutide, is covered for type 2 diabetes rather than for weight or cardiovascular risk in people without diabetes. The practical point: coverage follows the specific approved indication, not the molecule, so the right question is always which drug is approved for which condition on your plan.

How Soon Does the Heart Benefit Show Up?

In SELECT the event curves began separating within the first year and kept diverging across the full follow-up, which tells you the cardiovascular benefit is neither immediate nor a quick payoff you can measure in a month. It accrues the longer someone stays on the medication and holds onto the weight and blood pressure improvements. That has a direct implication for Medicare patients: this is a maintenance therapy, and stopping it likely surrenders much of the protection, the same way weight tends to return when the drug stops. Adherence over years, not a short trial of a few months, is what turns a trial result into a real-world drop in heart attacks and strokes.

What the Surge Means for Part D Premiums

Every new expensive drug that a large population becomes eligible for puts upward pressure on Part D. Wegovy is costly, the eligible group of older adults with heart disease and excess weight is enormous, and unlike a short course of antibiotics this is a drug people may take for years. Plans absorb that cost through premiums, formulary placement, tiering, and prior authorization, which is part of why coverage is discretionary rather than guaranteed and why some plans cover it while others do not. For beneficiaries, the practical fallout is uneven access: the same drug for the same diagnosis may be affordable on one plan and effectively out of reach on another, which makes the annual plan comparison during open enrollment more consequential than it used to be for anyone hoping to use Wegovy.

A Realistic Scenario

Consider a 68-year-old who had a heart attack three years ago, carries a BMI of 31, and does not have diabetes. Under the old rules, Medicare would not touch Wegovy for him because weight loss was the only on-label reason he might want it. Under the cardiovascular indication, his cardiologist can now prescribe it to lower his risk of a second event, his Part D plan may cover it if Wegovy is on the formulary, and the prior authorization hinges on his documented heart attack. If his plan does not list the drug, his choices narrow to switching plans at open enrollment, appealing the denial, or paying cash. That single example captures why the surge happened and why access is still uneven: the medical rationale is now clear, but the coverage plumbing varies plan by plan.

The broader lesson for anyone watching this trend is that the line between a weight-loss drug and a cardiovascular drug is drawn by evidence, not by marketing. Once a medication proves in a large trial that it prevents heart attacks and strokes, the coverage rules that once excluded it start to bend, because the drug is no longer only about the scale. That is why the smart move for a Medicare beneficiary is not to chase the headline but to confirm two specific things with a clinician: whether their heart history clears the indication, and whether their particular plan lists the drug this year.

Frequently Asked Questions

Does Medicare cover Wegovy for weight loss only?

No. Medicare does not cover drugs prescribed solely for weight loss due to a statutory exclusion. However, because Wegovy is now FDA-approved to reduce cardiovascular risk in certain patients, Medicare Part D plans may cover it for beneficiaries who have both obesity or overweight and established heart disease. The coverage is tied to the cardiovascular indication, not weight loss alone.

How quickly did prescriptions increase after the coverage expansion?

According to the original report by News-Medical, prescription claims for Wegovy among Medicare beneficiaries rose sharply within a short period after the policy change took effect. The spike was substantial enough to be noted in prescription data analytics, though exact percentages were not provided in the summary.

Will other weight loss drugs see similar Medicare coverage expansions?

Possibly. Medicare coverage for weight loss drugs is only possible if they receive FDA approval for a separate medical condition that is covered by Part D. Other medications in the GLP-1 class, such as Mounjaro and Zepbound, are also being studied for cardiovascular benefits. If they gain FDA approval for heart health indications, they may also become eligible for Medicare coverage.

Does the Medicare coverage apply if I only want Wegovy for weight loss?

No. The coverage pathway is tied to reducing cardiovascular risk in people who have established heart disease along with overweight or obesity. If your only goal is weight loss and you do not have documented cardiovascular disease, Medicare Part D still excludes the drug, and you would pay out of pocket.

Can I use a manufacturer coupon to lower my Medicare cost?

No. Federal rules bar people with Medicare or other government insurance from using manufacturer copay savings cards. Your realistic cost-lowering options are the Extra Help subsidy if you qualify by income and the annual Part D out-of-pocket cap.

What should I bring to my doctor to see if I qualify?

Bring records of any prior heart attack, stroke, or artery disease, your current medication list, and your Part D plan’s formulary status for Wegovy. The prescription needs to be written for cardiovascular risk reduction with the supporting diagnosis in the chart, so having that history documented is what makes a prior authorization succeed.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.